Severe acute respiratory syndrome coronavirus 2 infection in patients with hematological malignancies in the Omicron era: Respiratory failure, need for mechanical ventilation and mortality in seronegative and seropositive patients

eJHaem, Год журнала: 2024, Номер 5(3), С. 505 - 515

Опубликована: Апрель 9, 2024

Abstract Background Patients with hematological malignancies (HM) have a high risk of severe coronavirus disease 2019 (COVID‐19), also in the Omicron period. Material and methods Retrospective single‐center study including HM patients acute respiratory syndrome Coronavirus 2 (SARS‐CoV2) infection from January 2022 to March 2023. Study outcomes were failure (RF), mechanical ventilation (MV), COVID‐related mortality, comparing according SARS‐CoV2 serology. Results Note that, 112 included: 39% had negative Seronegative older (71.5 vs. 65.0 years, p = 0.04), more often lymphoid neoplasm (88.6% 69.1%, 0.02), underwent anti‐CD20 therapy (50.0% 30.9% 0.04) frequently (23.0% 3.0%, 0.02) than seropositive. Kaplan‐Meier showed higher for seronegative RF ( 0.014), MV 0.044), mortality 0.021). Negative serostatus resulted factor (hazards ratio [HR] 2.19, 95% confidence interval [CI] 1.03–4.67, (HR 3.37, CI 1.06–10.68, 4.26, 1.09–16.71, 0.04). Conclusions : serology, despite vaccinations previous infections, worse clinical compared seropositive era. The use serology diagnosis could be an easy tool identify prone developing complications.

Язык: Английский

---

Treatment of Persistent Coronavirus Disease 2019 (COVID-19) in a B Cell Acute Lymphoblastic Leukemia Patient with Using Nirmatrelvir/Ritonavir Extended Course: A Case Report

Journal of Infection and Public Health, Год журнала: 2024, Номер 17(10), С. 102526 - 102526

Опубликована: Авг. 24, 2024

Patients with hematological malignancies are at increased risk of persistent coronavirus disease 2019 (COVID-19) infection, a unique clinical condition, for which the optimal treatment is unknown. Here we report case COVID-19 in acute lymphoblastic leukemia (ALL) patient who successfully responded to extended course nirmatrelvir/ritonavir.

Язык: Английский

---

Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies

Multiple Sclerosis Journal, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 9, 2024

Organizing pneumonia (OP), an interstitial lung disease, has been observed in patients with inflammatory demyelinating diseases (IDDs) treated anti-CD20, particularly after COVID-19, but data are limited.

Язык: Английский

---

Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2023, Номер unknown

Опубликована: Апрель 12, 2023

Abstract Background Little data exists to guide the treatment of persistent COVID-19 in immunocompromised patients. We have employed a unique protocol combining tixegavimab/cilgavimab, and short-term combination antivirals including remdesivir. Methods A retrospective single-center analysis Response was assessed by symptom resolution, declining C-reactive protein (CRP) levels increasing SARS-CoV-2-PCR cycle-threshold (Ct) values. Results Fourteen patients were included, 2 kidney transplant recipients, 11 with B-cell lymphoproliferative disease, treated anti-CD20 or ibrutinib, 1 rheumatoid arthritis, anti-CD20. Median Ct-value 27 (interquartile range (IQR):24-32). All received tixegavimab/cilgavimab 5-day course Eleven also nirmaltrevir/ritonavir one molnupiravir. follow-up 45 days (IQR:12-89). had complete responses decrease CRP, increase Ct values (all either negative PCR value>30 on day 4-16). Three partial response relapses requiring re-admission. One died, two responded prolonged antiviral treatments. Conclusions monoclonal antibodies has led resolution most severely-immunocompromised Controlled studies will further direct these patients, while more effective are urgently needed. Key points Some develop symptomatic SARS-CoV-2 infection. Combination plus cured 11/14 Non-responders benefitted from treatment. trials needed find optimal COVID-19.

Язык: Английский

---

Direct and culture-independent detection of low-abundantClostridioides difficilein environmental DNA via PCR

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2023, Номер unknown

Опубликована: Июль 26, 2023

Abstract Clostridioides difficile represents a major burden to public health. As well-known nosocomial pathogen whose occurrence is highly associated with antibiotic treatment, most examined C. strains originated from clinical specimen and were isolated under selective conditions emplyoing antibiotics. This suggests significant bias among analysed strains, which impedes holistic view on this pathogen. In order support extensive isolation of environmental samples, we designed detection PCR that targets the hpdBCA operon thereby identifies low abundances in samples. Amplicon-based analyses diverse samples demonstrated specific for successfully detected despite its absence general 16S rRNA gene-based strategies. Further revealed potential sequence initial phylogenetic classification, allows assessing diversity via amplicon sequencing. Our findings furthermore showed treatment originally dominated by other according results. provided evidence cultivation under-represented but antibiotic-resistant isolates. Thereby, substantial research. Importance mainly responsible hospital-acquired infections after serious morbidity mortality worldwide. Research virulence focused bacterial implies strains. Comprehensive studies however require an unbiased strain collection, accomplished avoiding antibiotic-based enrichment Thus, can significantly benefit our -specific PCR, rapidly verifies presence further estimation using NGS.

Язык: Английский

---